Cogent Biosciences (COGT) Competitors $12.07 -0.12 (-0.98%) Closing price 07/25/2025 04:00 PM EasternExtended Trading$12.06 -0.01 (-0.08%) As of 07/25/2025 06:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock COGT vs. CRSP, PCVX, CYTK, MTSR, ADMA, KRYS, AKRO, RNA, PTCT, and ACLXShould you be buying Cogent Biosciences stock or one of its competitors? The main competitors of Cogent Biosciences include CRISPR Therapeutics (CRSP), Vaxcyte (PCVX), Cytokinetics (CYTK), Metsera (MTSR), ADMA Biologics (ADMA), Krystal Biotech (KRYS), Akero Therapeutics (AKRO), Avidity Biosciences (RNA), PTC Therapeutics (PTCT), and Arcellx (ACLX). These companies are all part of the "pharmaceutical products" industry. Cogent Biosciences vs. Its Competitors CRISPR Therapeutics Vaxcyte Cytokinetics Metsera ADMA Biologics Krystal Biotech Akero Therapeutics Avidity Biosciences PTC Therapeutics Arcellx Cogent Biosciences (NASDAQ:COGT) and CRISPR Therapeutics (NASDAQ:CRSP) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, valuation, dividends, profitability, institutional ownership, media sentiment, earnings and analyst recommendations. Does the media favor COGT or CRSP? In the previous week, CRISPR Therapeutics had 15 more articles in the media than Cogent Biosciences. MarketBeat recorded 18 mentions for CRISPR Therapeutics and 3 mentions for Cogent Biosciences. Cogent Biosciences' average media sentiment score of 0.90 beat CRISPR Therapeutics' score of 0.10 indicating that Cogent Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cogent Biosciences 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive CRISPR Therapeutics 5 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Is COGT or CRSP more profitable? Cogent Biosciences has a net margin of 0.00% compared to CRISPR Therapeutics' net margin of -1,023.64%. CRISPR Therapeutics' return on equity of -20.08% beat Cogent Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Cogent BiosciencesN/A -149.79% -75.61% CRISPR Therapeutics -1,023.64%-20.08%-17.13% Do institutionals and insiders believe in COGT or CRSP? 69.2% of CRISPR Therapeutics shares are owned by institutional investors. 7.3% of Cogent Biosciences shares are owned by company insiders. Comparatively, 4.3% of CRISPR Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Which has more volatility & risk, COGT or CRSP? Cogent Biosciences has a beta of 1.88, meaning that its share price is 88% more volatile than the S&P 500. Comparatively, CRISPR Therapeutics has a beta of 1.82, meaning that its share price is 82% more volatile than the S&P 500. Do analysts rate COGT or CRSP? Cogent Biosciences currently has a consensus target price of $18.70, indicating a potential upside of 54.93%. CRISPR Therapeutics has a consensus target price of $71.31, indicating a potential upside of 10.12%. Given Cogent Biosciences' stronger consensus rating and higher possible upside, research analysts plainly believe Cogent Biosciences is more favorable than CRISPR Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cogent Biosciences 0 Sell rating(s) 3 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 2.82CRISPR Therapeutics 1 Sell rating(s) 6 Hold rating(s) 10 Buy rating(s) 0 Strong Buy rating(s) 2.53 Which has higher earnings & valuation, COGT or CRSP? Cogent Biosciences has higher earnings, but lower revenue than CRISPR Therapeutics. CRISPR Therapeutics is trading at a lower price-to-earnings ratio than Cogent Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCogent BiosciencesN/AN/A-$255.86M-$1.84-6.56CRISPR Therapeutics$37.31M149.90-$366.25M-$4.52-14.33 SummaryCogent Biosciences beats CRISPR Therapeutics on 10 of the 16 factors compared between the two stocks. Get Cogent Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for COGT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding COGT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart COGT vs. The Competition Export to ExcelMetricCogent BiosciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.39B$3.05B$5.70B$9.50BDividend YieldN/A2.37%4.58%4.01%P/E Ratio-6.5621.1828.3920.08Price / SalesN/A281.42431.1989.30Price / CashN/A42.7636.2258.56Price / Book9.148.378.675.88Net Income-$255.86M-$55.19M$3.25B$258.89M7 Day Performance-3.36%5.86%4.25%3.71%1 Month Performance64.67%17.29%10.51%11.72%1 Year Performance26.79%4.39%35.71%18.00% Cogent Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)COGTCogent Biosciences3.6242 of 5 stars$12.07-1.0%$18.70+54.9%+30.9%$1.39BN/A-6.5680CRSPCRISPR Therapeutics2.4864 of 5 stars$56.42-0.7%$71.75+27.2%+12.5%$4.87B$37.31M-12.48460Analyst ForecastPCVXVaxcyte1.7979 of 5 stars$36.38+1.3%$136.50+275.2%-56.2%$4.69BN/A-9.12160News CoveragePositive NewsCYTKCytokinetics4.1471 of 5 stars$38.58+4.2%$70.92+83.8%-36.4%$4.61B$18.47M-7.29250News CoverageMTSRMetseraN/A$42.47+8.1%$55.00+29.5%N/A$4.46BN/A0.0081Lockup ExpirationGap DownADMAADMA Biologics3.6078 of 5 stars$18.68+0.9%$27.67+48.1%+37.7%$4.46B$426.45M21.98530News CoverageKRYSKrystal Biotech4.8906 of 5 stars$150.41+1.5%$213.75+42.1%-29.9%$4.35B$290.52M36.16210News CoverageAnalyst ForecastAKROAkero Therapeutics3.81 of 5 stars$52.73+2.2%$82.50+56.5%+78.5%$4.20BN/A-27.0430Positive NewsRNAAvidity Biosciences2.1407 of 5 stars$33.57+6.7%$66.35+97.7%-18.9%$4.05B$8.93M-11.19190News CoverageHigh Trading VolumePTCTPTC Therapeutics4.4429 of 5 stars$49.46+1.9%$65.00+31.4%+33.3%$3.92B$806.78M7.601,410News CoverageAnalyst RevisionACLXArcellx2.286 of 5 stars$69.92+1.4%$111.23+59.1%+13.8%$3.85B$76.81M-23.3880News CoveragePositive News Related Companies and Tools Related Companies CRISPR Therapeutics Alternatives Vaxcyte Alternatives Cytokinetics Alternatives Metsera Alternatives ADMA Biologics Alternatives Krystal Biotech Alternatives Akero Therapeutics Alternatives Avidity Biosciences Alternatives PTC Therapeutics Alternatives Arcellx Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:COGT) was last updated on 7/26/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump’s $100 Trillion Land Rush Is OnWhat Is "The US: IPO"? You won't hear this on CNBC... but the government may soon open up hundreds of trill...Stansberry Research | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | SponsoredForget Nvidia, This “Ghost Town” Company Holds the Key to the AI BoomCold War Discovery Could Unlock $100 Trillion in Wealth Jeff recently traveled to an American ghost town to...Brownstone Research | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cogent Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cogent Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free COGT Stock Alerts